Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Increase in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 47,507 shares, a growth of 1,454.0% from the April 30th total of 3,057 shares. Based on an average daily trading volume, of 651,410 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Daiichi Sankyo Trading Down 0.7%

DSNKY traded down $0.11 during mid-day trading on Wednesday, hitting $16.81. The stock had a trading volume of 196,924 shares, compared to its average volume of 312,341. The stock’s fifty day simple moving average is $17.47 and its 200-day simple moving average is $19.64. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85. The firm has a market capitalization of $31.84 billion, a price-to-earnings ratio of 17.88, a price-to-earnings-growth ratio of 1.21 and a beta of -0.25. Daiichi Sankyo has a 1-year low of $15.56 and a 1-year high of $28.21.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, research analysts forecast that Daiichi Sankyo will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Daiichi Sankyo currently has an average rating of “Buy”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.